Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$38.19

-2.74 (-6.69%)

07:45
08/09/17
08/09
07:45
08/09/17
07:45

Mallinckrodt selloff after earnings not warranted, says UBS

UBS analyst Marc Goodman said the selloff in Mallinckrodt following Q2 results was not warranted as the quarterly report did nothing to change his view on the shares. He said the shares sold off ahead of its earnings report on concerns of generic drug pricing and since it didn't materialize, the weakness is a buying opportunity. Goodman reiterated his Buy rating and $70 price target on Mallinckrodt shares.

MNK Mallinckrodt
$38.19

-2.74 (-6.69%)

07/13/17
WELS
07/13/17
NO CHANGE
WELS
Outperform
Wells says Mallinckrodt orphan news a 'good reminder' of pipline opportunties
Wells Fargo analyst David Maris said Mallinckrodt's announcement last night that that the FDA has granted orphan drug designation to its muscular dystrophy drug, MNK-1411, is a good reminder of the companies pipeline "shots on goal" that he does not believe are factored well enough in investor expectations. Maris keeps an Outperform rating on Mallinckrodt shares, citing the stock's valuation.
08/02/17
JEFF
08/02/17
NO CHANGE
Target $70
JEFF
Buy
After FOIA request, Jefferies calls Acthar adverse events 'minimal'
After obtaining the adverse events for Mallinckrodt's Acthar reported to FAERS database dating back to 2010 via a Freedom of Information Act request, Jefferies analyst Anthony Petrone says the drug's overall adverse events are minimal in the context of usage and relative to other drug categories. Further, the mortality rate of the drug is "de minimis" over past seven years, Petrone tells investors in a research note. The treatment uses of Acthar include select cases of systemic lupus erythematosus, infantile spasms and acute exacerbations of multiple sclerosis. The FDA Adverse Event Reporting System, or FAERS, is a database that contains information on adverse event and medication error reports submitted to FDA. The analyst also points out that Acthar adverse events and deaths are in decline since 2015. On the prescription front, trends point toward a "favorable Acthar print" in Q2, Petrone writes in his note. He has a Buy rating on Mallinckrodt with a $70 price target. The pharmaceutical company closed yesterday down $1.29 to $44.51.
08/04/17
BMOC
08/04/17
NO CHANGE
Target $69
BMOC
Outperform
Mallinckrodt acquisition of InfaCare a 'nice addition,' says BMO Capital
BMO Capital analyst Gary Nachman views Mallinckrodt's acquisition of InfaCare as a "nice addition to an already strong hospital franchise." The analyst thinks InfaCare's Stannsoporfin is "durable" late-stage asset for severe jaundice that could be on the market in late 2018. Nachman likes "low-risk tuck-in deals" and keeps an Outperform rating on Mallinckrodt with a $69 price target.
08/07/17
PIPR
08/07/17
NO CHANGE
Target $85
PIPR
Overweight
Piper stays bullish on shares of Mallinckrodt
Piper Jaffray analyst David Amsellem says the acquisition of InfaCar brings to Mallinckrodt another late-stage asset that can leverage the company's existing hospital/acute care commercial infrastructure. The analyst expects management will continue to execute on the acquisition of pipeline or market-ready assets. He stays bullish on Mallinckrodt shares with an Overweight rating and $85 price target.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:08
11/23/17
11/23
08:08
11/23/17
08:08
Hot Stocks
Tesla CEO highlights 'record time' on Australian ion battery »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:07
11/23/17
11/23
08:07
11/23/17
08:07
Hot Stocks
Tesla completes construction on largest lithium ion battery in Australia »

The South Australian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

, INVA

Innoviva

$13.42

0.01 (0.07%)

07:56
11/23/17
11/23
07:56
11/23/17
07:56
Hot Stocks
GSK, Innoviva submit data to FDA for expanded Trelegy Ellipta label »

GlaxoSmithKline (GSK) and…

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

INVA

Innoviva

$13.42

0.01 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVM

Silvercorp Metals

$2.51

-0.07 (-2.71%)

07:52
11/23/17
11/23
07:52
11/23/17
07:52
Hot Stocks
Silvercorp Metals to buy back up to 5% of shares »

Silvercorp Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$10.00

-0.1 (-0.99%)

07:49
11/23/17
11/23
07:49
11/23/17
07:49
Hot Stocks
Cellcom Israel now second layer company according to Concentration Law »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GASS

StealthGas

$4.07

0.36 (9.70%)

07:06
11/23/17
11/23
07:06
11/23/17
07:06
Recommendations
StealthGas analyst commentary  »

StealthGas trades at only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$41.01

4.31 (11.74%)

07:02
11/23/17
11/23
07:02
11/23/17
07:02
Recommendations
Copart analyst commentary  »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DE

Deere

$145.25

6.02 (4.32%)

06:56
11/23/17
11/23
06:56
11/23/17
06:56
Upgrade
Deere rating change  »

Deere upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DE

Deere

$145.25

6.02 (4.32%)

06:55
11/23/17
11/23
06:55
11/23/17
06:55
Recommendations
Deere analyst commentary  »

Deere price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

06:40
11/23/17
11/23
06:40
11/23/17
06:40
General news
FX Update: The dollar has remained on a weakening track »

FX Update: The dollar has…

SECO

Seeco Holding

$8.34

0.14 (1.71%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Seeco Holding management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Deutsche Bank to hold a conference »

Thailand SET Corporate…

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

04:25
11/23/17
11/23
04:25
11/23/17
04:25
General news
FX Action: USD-CAD punched out a 10-day low »

FX Action: USD-CAD…

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$180.87

-0.99 (-0.54%)

17:47
11/22/17
11/22
17:47
11/22/17
17:47
Periodicals
Facebook tool to show users which content was Russian propaganda, says Bloomberg »

Facebook will add a tool…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$51.01

0.79 (1.57%)

17:24
11/22/17
11/22
17:24
11/22/17
17:24
Periodicals
CSX to charge more fees on customers that disregard shipping rules, Reuters says »

Starting on January 1st,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AYTU

Aytu BioScience

$3.03

0.4301 (16.54%)

17:10
11/22/17
11/22
17:10
11/22/17
17:10
Syndicate
Breaking Syndicate news story on Aytu BioScience »

Aytu BioScience files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPIX

ESSA Pharma

$0.27

0.0059 (2.27%)

17:09
11/22/17
11/22
17:09
11/22/17
17:09
Hot Stocks
ESSA Pharma to begin trading on TSX Venture Exchange »

ESSA Pharma is listing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.